The expensive mistake is not a weak chart.
It is charting against the wrong company.
IP8 starts from your portfolio, ranks what is worth asserting, finds the products already reading on those claims, and builds the evidence, so the costly work begins on opportunities that were chosen rather than noticed.
patent?
using it?
survive?
Target selection is the programme,
and it is rarely a process.
The list comes from somewhere unscientific, a competitor everyone watches, a product an engineer mentioned in a meeting, or a company from a licensing conversation years ago that stuck in someone's memory. Then the expensive part starts (evidence of use, claim charts, outside counsel, sometimes months of it) on a target selected by accident.
The failures are invisible too: the licensee never found, the mid-size manufacturer in an untracked market, the feature added quietly in an old software release. You cannot miss a licensee you never heard of; you just never see the revenue.
Which patent, who is using it,
and would it survive.
Rank the assets. Find the users. Stress-test the patent. Then spend the money.
Opportunities that keep developing
after you find them.
A monetization programme is an ongoing pipeline. IP8 continuously scans for new products and signals, alerting you when evidence crosses your threshold so weak mappings strengthen automatically without rerunning analysis.
“We used the portfolio assertability output to find which patents and claims would be most useful against a target product. That output went straight into licensing conversations.”
“The evidence-of-use reports are structured and citation-backed, so our attorneys can work from them directly rather than starting from scratch.”
Bring the next patent decision to IP8.
Turn your portfolio into a continuous monetization pipeline with verified evidence of use.
